Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 423

1.

Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.

Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S.

Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4162-7. Epub 2003 Mar 12.

2.

Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein.

Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ.

Am J Pathol. 2004 Apr;164(4):1425-34.

4.

Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death.

Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ.

Neuron. 2003 Dec 18;40(6):1087-93.

5.

[Alzheimer disease: cellular and molecular aspects].

Octave JN.

Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1. French.

PMID:
16768248
6.

Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures.

Lynch JA, George AM, Eisenhauer PB, Conn K, Gao W, Carreras I, Wells JM, McKee A, Ullman MD, Fine RE.

J Neurosci Res. 2006 May 15;83(7):1262-70.

PMID:
16511862
7.

IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia.

Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H.

J Immunol. 2008 Nov 1;181(9):6503-13.

8.
9.

Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.

Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ.

Biochemistry. 2005 May 3;44(17):6513-25.

PMID:
15850385
10.
11.

Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice.

Li F, Calingasan NY, Yu F, Mauck WM, Toidze M, Almeida CG, Takahashi RH, Carlson GA, Flint Beal M, Lin MT, Gouras GK.

J Neurochem. 2004 Jun;89(5):1308-12.

12.

ApoE 4 reduces the expression of Abeta degrading enzyme IDE by activating the NMDA receptor in hippocampal neurons.

Du J, Chang J, Guo S, Zhang Q, Wang Z.

Neurosci Lett. 2009 Oct 23;464(2):140-5. doi: 10.1016/j.neulet.2009.07.032. Epub 2009 Jul 16.

PMID:
19616072
13.
14.

Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease.

Zuo X, Jia J.

Brain Res. 2009 Jan 16;1249:1-8. doi: 10.1016/j.brainres.2008.10.034. Epub 2008 Oct 28.

PMID:
18996360
15.

Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.

Velliquette RA, O'Connor T, Vassar R.

J Neurosci. 2005 Nov 23;25(47):10874-83. Erratum in: J Neurosci. 2006 Feb 15;26(7):2140-2.

16.

Down-regulation of insulin-degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42.

Qin W, Jia J.

Eur J Neurosci. 2008 May;27(9):2425-32. doi: 10.1111/j.1460-9568.2008.06207.x.

PMID:
18445230
17.

Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.

van Groen T, Kiliaan AJ, Kadish I.

Neurobiol Dis. 2006 Sep;23(3):653-62. Epub 2006 Jul 10.

PMID:
16829076
18.
19.

Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease.

Fernández-Gamba A, Leal MC, Morelli L, Castaño EM.

Curr Pharm Des. 2009;15(31):3644-55. Review.

PMID:
19925417
20.

Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor.

Ling X, Martins RN, Racchi M, Craft S, Helmerhorst E.

J Alzheimers Dis. 2002 Oct;4(5):369-74.

PMID:
12446969

Supplemental Content

Support Center